Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Promising start to 2022 Q1 2022 highlights Total net revenues of SEK 159.4 m (132.3) EBITDA of SEK 2.8 m (-23.9) Net earnings of SEK -23.6 m (-31.5)...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248),...
Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 21 April 2022 resolved, in accordance with the...
Orexo's Annual Report for the 2021 has been published. The Annual Report can be downloaded on the company's website, www.orexo.com, and a PDF is...
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company has appointed Fredrik Järrsten as new Chief Financial Officer (CFO) and a ...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today information about improved market access position for ZUBSOLV® (buprenorphine and...
Ready to capitalize on a strong foundation Q4 2021 highlights Total net revenues of SEK 144.0 m (159.2) Net earnings of SEK -66.0 m (-49.6) EBITDA of ...
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today provides information about its new proprietary drug delivery platform, amorphOXTM, a novel and...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully completed the pivotal trial (OX124-002) for its lead...
Q3 2021 highlights Total net revenues of SEK 145.9 m (150.3) Net earnings of -52.0 SEK m (-84.9) EBITDA of SEK -47.4 m (-20.9) US Pharma segment...
Prior to the Annual General Meeting (AGM) in 2022, Orexo has appointed a Nomination Committee which represents approximately 38 percent of the number ...
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead...
"First commercial DTx contract signed with a large healthcare provider" Summary Total net revenues of SEK 142.8 m (179.1) Net earnings of SEK -73.7 m ...
Sober Grid, the largest social media network for those in addiction recovery, and Orexo, a Swedish pharmaceutical company, today announced that Sober ...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) and Sober Grid, the largest social media network for those in addiction recovery, today announced that...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office (USPTO) has issued another two patents relating to...
Q1 2021 summary Total net revenues of SEK 132.3 m (175.0) Net earnings of SEK -31.5 m (82.6) EBITDA of SEK -23.9 m (39.1) US Pharma segment (ZUBSOLV® ...
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research ...
Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) ") has today given notice to all holders of the Company's maximum SEK...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.